Birchview Capital, LP
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Schedule 13D/13G stakes
Stakes of 5% or more disclosed on Schedule 13D or 13G, each on the filer's latest filing for the security. These are event-dated stakes, not the quarter-end 13F portfolio below.
| Company | Schedule | Event date | Filed | Shares | % of class | Status |
|---|---|---|---|---|---|---|
| ELUT Elutia Inc. | 13G/A | Dec 31, 2023 | 2y | 1,655,184 | 8.76% | Unconfirmed since Dec 31, 2023 |
A 13D or 13G stays in force until its filer amends it and no amendment is due without a material change, so a stake with no filing in 24 months reads unconfirmed, never sold. An amendment reporting under 5% ends the filer's duty to amend, not necessarily the holding. Shares are restated onto today's split basis.
Portfolio style
Measured from the filed 13F common-share book for Sep 30, 2026, never from the firm's own description.
Closest benchmark: the Nasdaq-100 as of 2026-08-31, active share 97.3%; sector active share 59.8% against the combined 13F book's sector weights.
Over time 27 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+. Stocks and the top 10 weight count issuers: share classes of one company are one stock, and options are left out, so they can differ from the position count and top 10 concentration of GetInstitutionSummary and GetInstitutionPortfolio, which count each listed share class.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
73 common stock positions · as of Sep 30, 2026 · Δ vs Jun 30, 2026Portfolio Trend
Sector Breakdown
Common stock positions · as of Sep 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 68.3% | $114,659,480 |
| Technology | 25.3% | $42,396,524 |
| Energy | 4.7% | $7,896,748 |
| Financial Services | 1.0% | $1,619,818 |
| Basic Materials | 0.8% | $1,261,890 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| ADAG | Adagene Inc. | +190,000 | 430,000 | $1,376,000 | |
| VYGR | Voyager Therapeutics, Inc. | +149,771 | 224,918 | $602,780 | |
| SLDB | Solid Biosciences Inc. | +49,759 | 715,955 | $5,176,354 | |
| DFTX | Definium Therapeutics, Inc. | +32,000 | 52,000 | $1,979,120 | |
| XENE | Xenon Pharmaceuticals Inc. | +21,963 | 42,995 | $1,598,984 | |
| BBIO | BridgeBio Pharma, Inc. | +10,000 | 18,741 | $1,233,157 | |
| CSTL | Castle Biosciences Inc | +9,951 | 22,935 | $814,880 | |
| ALT | Altimmune, Inc. | +8,283 | 160,964 | $460,357 | |
| VIR | Vir Biotechnology, Inc. | +6,992 | 226,992 | $2,537,770 | |
| IMNM | Immunome Inc. | +5,600 | 55,600 | $1,195,956 | |
| ABVX | Abivax S.A. | +4,000 | 21,000 | $2,079,420 | |
| FHTX | Foghorn Therapeutics Inc. | +370 | 282,307 | $1,007,835 | |
| HALO | Halozyme Therapeutics, Inc. | +100 | 33,351 | $3,681,950 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| PACB | Pacific Biosciences Of California, Inc. | −1,190,000 | 160,000 | $379,200 | |
| IVVD | Invivyd, Inc. | −266,300 | 75,975 | $66,105 | |
| OLMA | Olema Oncology, Inc. | −140,000 | 59,000 | $509,760 | |
| BCYC | Bicycle Therapeutics PLC | −137,184 | 176,432 | $649,269 | |
| NTLA | Intellia Therapeutics, Inc. | −104,535 | 281,365 | $3,393,261 | |
| CMPX | Compass Therapeutics, Inc. | −100,000 | 1,575,000 | $1,638,000 | |
| BMY | Bristol Myers Squibb Co | −72,998 | 224,245 | $13,992,888 | |
| SLN | Silence Therapeutics plc | −41,218 | 30,000 | $327,900 | |
| STOK | Stoke Therapeutics, Inc. | −40,110 | 138,000 | $3,588,000 | |
| NKTR | Nektar Therapeutics | −35,000 | 46,000 | $2,785,070 | |
| CLDX | Celldex Therapeutics, Inc. | −12,700 | 57,200 | $1,853,852 | |
| KLAC | Kla Corp | −11,533 | 166,938 | $32,541,224 | |
| LRCX | Lam Research Corp | −5,000 | 30,000 | $9,855,300 | |
| TVTX | Travere Therapeutics, Inc. | −4,000 | 25,000 | $1,472,000 | |
| UTHR | UNITED THERAPEUTICS Corp | −2,006 | 2,500 | $1,354,725 | |
| NBIX | Neurocrine Biosciences Inc | −2,000 | 25,190 | $3,572,949 | |
| CORT | Corcept Therapeutics Inc | −2,000 | 55,200 | $6,360,696 | |
| LUNG | Pulmonx Corp | −543 | 200,000 | $382,000 | |
| ZBIO | Zenas BioPharma, Inc. | −221 | 93,380 | $2,518,458 | |
| OCUL | Ocular Therapeutix, Inc | −205 | 20,450 | $156,851 | |
| PTGX | Protagonist Therapeutics, Inc | −18 | 35,000 | $4,931,150 | |
| FCX | Freeport-Mcmoran Inc | −8 | 18,027 | $1,261,890 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc. | 373,671 | $5,616,275 | |
| QNCX | IRulya Therapeutics Inc. | 40,601 | $1,259,037 | |
| VALN | Valneva SE | 201,390 | $1,245,597 | |
| JATT | JATT II Acquisition Corp. | 90,455 | $1,017,618 | |
| BLSM | BlossomHill Therapeutics, Inc. | 50,000 | $932,000 | |
| DRUG | Bright Minds Biosciences Inc. | 15,400 | $767,228 | |
| SLGL | Sol-Gel Technologies Ltd. | 7,600 | $564,528 | |
| CRMD | CorMedix Inc. | 65,874 | $507,229 | |
| ABEO | Abeona Therapeutics Inc. | 90,700 | $476,175 | |
| VOR | Vor Biopharma Inc. | 24,000 | $457,920 | |
| MLTX | MoonLake Immunotherapeutics | 36,220 | $423,774 | |
| AEMD | Aethlon Medical Inc | 62,837 | $409,697 | |
| RZLT | Rezolute, Inc. | 60,296 | $249,625 | |
| TRDA | Entrada Therapeutics, Inc. | 36,849 | $233,991 | |
| IMUX | Immunic, Inc. | 21,917 | $203,828 | |
| CRDL | Cardiol Therapeutics Inc. | 100,000 | $166,000 | |
| BMEA | Biomea Fusion, Inc. | 93,500 | $124,355 | |
| GUTS | Fractyl Health, Inc. | 165,478 | $90,020 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| VERA | Vera Therapeutics, Inc. | 57,758 | $2,478,395 | |
| QURE | uniQure N.V. | 50,697 | $2,335,103 | |
| BIOA | BioAge Labs, Inc. | 69,000 | $1,691,190 | |
| GPCR | Structure Therapeutics Inc. | 24,000 | $1,288,080 | |
| NVO | Novo Nordisk A S | 24,000 | $1,150,560 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 48,505 | $645,116 | |
| URGN | UroGen Pharma Ltd. | 16,487 | $606,721 | |
| PHAT | Phathom Pharmaceuticals, Inc. | 55,000 | $596,750 | |
| SVRA | Savara Inc | 80,000 | $492,800 | |
| CADL | Candel Therapeutics, Inc. | 47,756 | $491,886 | |
| CMPS | COMPASS Pathways plc | 30,000 | $424,500 | |
| KPTI | Karyopharm Therapeutics Inc. | 42,952 | $419,641 | |
| CAPR | Capricor Therapeutics, Inc. | 14,352 | $345,596 | |
| GRCE | Grace Therapeutics, Inc. | 120,000 | $272,400 | |
| QNRX | Quoin Pharmaceuticals Ltd. | 20,000 | $96,800 | |
| GOSS | Gossamer Bio, Inc. | 227 | $2,999 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| KLAC |
Kla Corp
Technology
|
Reduced | 166,938 | $32,541,224 | 19.39% | |
| BMY |
Bristol Myers Squibb Co
Healthcare
|
Reduced | 224,245 | $13,992,888 | 8.34% | |
| LRCX |
Lam Research Corp
Technology
|
Reduced | 30,000 | $9,855,300 | 5.87% | |
| BDSX |
Biodesix Inc
Healthcare
|
Held | 286,804 | $8,555,363 | 5.10% | |
| CORT |
Corcept Therapeutics Inc
Healthcare
|
Reduced | 55,200 | $6,360,696 | 3.79% | |
| OVV |
Ovintiv Inc.
Energy
|
Held | 107,500 | $6,215,650 | 3.70% | |
| RARE |
Ultragenyx Pharmaceutical Inc.
Healthcare
|
NEW | 373,671 | $5,616,275 | 3.35% | |
| SLDB |
Solid Biosciences Inc.
Healthcare
|
Added | 715,955 | $5,176,354 | 3.08% | |
| PTGX |
Protagonist Therapeutics, Inc
Healthcare
|
Reduced | 35,000 | $4,931,150 | 2.94% | |
| PRTA |
Prothena Corp Public Ltd Co
Healthcare
|
Held | 449,019 | $3,762,779 | 2.24% | |
| HALO |
Halozyme Therapeutics, Inc.
Healthcare
|
Added | 33,351 | $3,681,950 | 2.19% | |
| STOK |
Stoke Therapeutics, Inc.
Healthcare
|
Reduced | 138,000 | $3,588,000 | 2.14% | |
| NBIX |
Neurocrine Biosciences Inc
Healthcare
|
Reduced | 25,190 | $3,572,949 | 2.13% | |
| ACAD |
Acadia Pharmaceuticals Inc
Healthcare
|
Held | 171,000 | $3,445,650 | 2.05% | |
| NTLA |
Intellia Therapeutics, Inc.
Healthcare
|
Reduced | 281,365 | $3,393,261 | 2.02% | |
| NKTR |
Nektar Therapeutics
Healthcare
|
Reduced | 46,000 | $2,785,070 | 1.66% | |
| VIR |
Vir Biotechnology, Inc.
Healthcare
|
Added | 226,992 | $2,537,770 | 1.51% | |
| ZBIO |
Zenas BioPharma, Inc.
Healthcare
|
Reduced | 93,380 | $2,518,458 | 1.50% | |
| ABVX |
Abivax S.A.
Healthcare
|
Added | 21,000 | $2,079,420 | 1.24% | |
| BIIB |
Biogen Inc.
Healthcare
|
Held | 9,000 | $2,032,920 | 1.21% | |
| ALKS |
Alkermes plc.
Healthcare
|
Held | 50,000 | $2,026,000 | 1.21% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
Added | 52,000 | $1,979,120 | 1.18% | |
| CYTK |
Cytokinetics Inc
Healthcare
|
Held | 30,000 | $1,977,300 | 1.18% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Reduced | 57,200 | $1,853,852 | 1.10% | |
| EQT |
EQT Corp
Energy
|
Held | 34,619 | $1,681,098 | 1.00% | |
| CMPX |
Compass Therapeutics, Inc.
Healthcare
|
Reduced | 1,575,000 | $1,638,000 | 0.98% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Added | 42,995 | $1,598,984 | 0.95% | |
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
Held | 408,100 | $1,538,537 | 0.92% | |
| TVTX |
Travere Therapeutics, Inc.
Healthcare
|
Reduced | 25,000 | $1,472,000 | 0.88% | |
| ADAG |
Adagene Inc.
Healthcare
|
Added | 430,000 | $1,376,000 | 0.82% | |
| UTHR |
UNITED THERAPEUTICS Corp
Healthcare
|
Reduced | 2,500 | $1,354,725 | 0.81% | |
| FCX |
Freeport-Mcmoran Inc
Basic Materials
|
Reduced | 18,027 | $1,261,890 | 0.75% | |
| QNCX |
IRulya Therapeutics Inc.
Healthcare
|
NEW | 40,601 | $1,259,037 | 0.75% | |
| VALN |
Valneva SE
Healthcare
|
NEW | 201,390 | $1,245,597 | 0.74% | |
| BBIO |
BridgeBio Pharma, Inc.
Healthcare
|
Added | 18,741 | $1,233,157 | 0.73% | |
| IMNM |
Immunome Inc.
Healthcare
|
Added | 55,600 | $1,195,956 | 0.71% | |
| AXSM |
Axsome Therapeutics, Inc.
Healthcare
|
Held | 6,000 | $1,106,340 | 0.66% | |
| JATT |
JATT II Acquisition Corp.
Financial Services
|
NEW | 90,455 | $1,017,618 | 0.61% | |
| FHTX |
Foghorn Therapeutics Inc.
Healthcare
|
Added | 282,307 | $1,007,835 | 0.60% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Held | 29,847 | $946,746 | 0.56% | |
| BLSM |
BlossomHill Therapeutics, Inc.
Healthcare
|
NEW | 50,000 | $932,000 | 0.56% | |
| CSTL |
Castle Biosciences Inc
Healthcare
|
Added | 22,935 | $814,880 | 0.49% | |
| DRUG |
Bright Minds Biosciences Inc.
Healthcare
|
NEW | 15,400 | $767,228 | 0.46% | |
| HROW |
Harrow, Inc.
Healthcare
|
Held | 24,000 | $739,200 | 0.44% | |
| BCYC |
Bicycle Therapeutics PLC
Healthcare
|
Reduced | 176,432 | $649,269 | 0.39% | |
| VYGR |
Voyager Therapeutics, Inc.
Healthcare
|
Added | 224,918 | $602,780 | 0.36% | |
| SLGL |
Sol-Gel Technologies Ltd.
Healthcare
|
NEW | 7,600 | $564,528 | 0.34% | |
| OLMA |
Olema Oncology, Inc.
Healthcare
|
Reduced | 59,000 | $509,760 | 0.30% | |
| CRMD |
CorMedix Inc.
Healthcare
|
NEW | 65,874 | $507,229 | 0.30% | |
| CAMP |
Camp4 Therapeutics Corp
Healthcare
|
Held | 120,000 | $484,800 | 0.29% |
Showing the top 50 of 73 positions. Create a free account to see every position, past quarters, search, filters and CSV export.
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.